ALK+ ALCL expresses CD30, PD-L1, and B7-H3, which are potential therapeutic targets for promoting tumor cell death through pathways independent of ALK, thereby overcoming ALK TKI resistance. Here, TNFRSF8 is linked to anaplastic large cell lymphoma.